Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
Cyclacel Pharmaceuticals, Inc. (CYCC) Tops Q2 EPS by 8c
August 12, 2014 5:11 PM EDTCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q2 EPS of ($0.22), $0.08 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $264 thousand, versus $356 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.
... More


